Alkermes plc (ALKS) | Stock Overview & Key Data
Alkermes plc Performance Comparison
Stock Range
Today's Range
Low: $28.38
High: $29.12
on August 15, 2025
52 Week Range
Low: $25.56
High: $36.45
on April 10, 2025
on February 18, 2025
All-Time High: $98.50 on February 28, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$4.8B
EPS
2.07
P/E Ratio (TTM)
14.03
Forward P/E
14.45
P/B Ratio
2.95
PEG Ratio
-7.58
Div. Yield
N/A
ROE
23.94%
Beta
0.425
Debt to Equity
4.47
Financial Highlights
Profitability
Gross Margin
87.34%
Operating Margin
23.80%
Profit Margin
23.15%
Returns and Earnings
Return on Assets (TTM)
10.49%
Return on Equity (TTM)
23.94%
EBITDA
$450.2M
Net Income (TTM)
$348.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$9.28
Quarterly Revenue Growth (YoY)
-2.10%
Quarterly Earnings Growth (YoY)
-4.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alkermes plc ALKS | 4.80B Mid-cap | 8.76% | 0.69% | -6.92% | -19.08% | 1.04% | 6.61% | 15.00% | 70.18% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.57B Large-cap | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% | -0.31% | 61.37% | 30.23% |
| Elanco Animal Health ELAN | 8.66B Mid-cap | 7.74% | 22.93% | 38.79% | 58.66% | 49.05% | 23.95% | 2.80% | -33.73% |
| Regencell Bioscience RGC | 6.65B Mid-cap | -6.08% | -4.23% | 24.01% | 13,020.00% | 9,992.31% | 5,863.64% | 1,443.53% | 4,585.71% |
| Prestige Consumer PBH | 3.79B Mid-cap | -0.90% | -13.52% | -25.39% | -23.71% | -16.38% | -5.19% | 14.08% | 74.66% |
Ownership & Short Interest
Insider Ownership
1.49%
Institutional Ownership
105.26%
Shares Short
14M
Short Ratio
6.35
Short % of Shares Outstanding
12.14%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Alkermes plc Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Alkermes plc would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALKS's 52-week high and low?
- In the last 52 weeks, Alkermes plc reached a high of $36.45 (on February 18, 2025) and a low of $25.56 (on April 10, 2025).
- What is the market cap and P/E ratio for ALKS?
- Curious about Alkermes plc's size and valuation? Its market capitalization stands at 4.80B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.03, and the forward P/E (looking ahead) is 14.45.
- Does ALKS pay dividends? If so, what's the yield?
- As for dividends, Alkermes plc isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alkermes plc's main competitors or similar companies to consider before investing?
When looking at Alkermes plc, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.57B Healthcare Drug Manufacturers - Specialty & Generic -0.31% 61.37% Elanco Animal Health
ELAN8.66B Healthcare Drug Manufacturers - Specialty & Generic 23.95% 2.80% Regencell Bioscience
RGC6.65B Healthcare Drug Manufacturers - Specialty & Generic 5,863.64% 1,443.53% Prestige Consumer
PBH3.79B Healthcare Drug Manufacturers - Specialty & Generic -5.19% 14.08% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alkermes plc? (e.g., ROE, Debt/Equity)
- To get a sense of Alkermes plc's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 23.94%, the Debt to Equity ratio from the most recent quarter is 4.47, and its Gross Profit Margin stands at 87.34%.
- What is the recent revenue and earnings growth for ALKS?
- Looking at Alkermes plc's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.10%, and quarterly earnings saw a YoY growth of -4.70%.
- How much of ALKS stock is held by insiders and institutions?
- Wondering who owns Alkermes plc stock? Company insiders (like executives and directors) hold about 1.49% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 105.26%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.